ReviewFrontiers in medicine2024
Chronic obstructive pulmonary disease (COPD) and COPD-like phenotypes.
Review in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Translational prioritization of genetically supported candidate targets and pharmacological annotations for chronic lung diseases: a single-cell eQTL-guided multi-cohort study.Journal of translational medicine · 2026Article
- Predicting the progression risk of chronic obstructive pulmonary disease in high-risk individuals based on whole-lung radiomics and deep learning: a multicenter study.Journal of thoracic disease · 2026Article
- AI in respiratory care: findings from the GOLD report.Journal of translational medicine · 2026Article
- Impact of Multidisciplinary Team-Based Nursing on Pulmonary and Psychological Outcomes in Acute Exacerbation of Chronic Obstructive Pulmonary Disease.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- The Evolving Landscape of COPD Typization.Medicina (Kaunas, Lithuania) · 2026Review
- Cluster Analysis of Healthcare Utilization Patterns in Patients with Comorbid Chronic Obstructive Pulmonary Disease and Atrial Fibrillation.Journal of clinical medicine · 2026Article
- SULT1E1 exerts a protective role in COPD by inhibiting the AKT pathway: an in vivo and in vitro study.Scientific reports · 2026Article
- The role of the gut-lung axis in persistent inflammation and disease progression in chronic obstructive pulmonary disease: mechanistic evidence and therapeutic implications.Frontiers in immunology · 2026Review
- Evolving relationships between air pollution attenuation and AECOPD hospitalizations during a stringent control period in Shijiazhuang, China, 2017-2024.Frontiers in public health · 2026Article
- Research Progress and Comparative Evaluation of Three Cutting-Edge Chronic Obstructive Pulmonary Disease Treatment Strategies: Biologics, Bronchoscopic Lung Volume Reduction, and Stem Cell Therapies.International journal of chronic obstructive pulmonary disease · 2026Review
- Chest CT imaging for differentiating normal, PRISm, and COPD in comparison with pulmonary function tests.La Radiologia medica · 2025Article
- Lung MRI scoring reveals persistence of emphysema-like changes in lungs of infants born preterm at (pre)school age.ERJ open research · 2025Article
- Phenotypes of Exacerbations in Chronic Obstructive Pulmonary Disease.Journal of clinical medicine · 2025Review
- Inhibition of Inflammatory Regulators for Chronic Obstructive Pulmonary Disease (COPD) Treatment from Indonesian Medicinal Plants: A Systematic Review.Current issues in molecular biology · 2025Review
- Potential active ingredients and mechanisms of Shufeitie ointment in the treatment of chronic obstructive pulmonary disease by integrating transdermal chemistry and network pharmacology.Frontiers in medicine · 2025Article
- Fezakinumab Alleviates Cigarette Smoke-Induced COPD by Suppressing the JAK1/STAT3 Pathway in Mice.Canadian respiratory journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease. Historically, two COPD phenotypes have been described: chronic bronchitis and emphysema. Although these phenotypes may provide additional characterization of the pathophysiology of the disease, they are not extensive enough to reflect the heterogeneity of COPD and do not provide granular categorization that indicates specific treatment, perhaps with the exception of adding inhaled glucocorticoids (ICS) in patients with chronic bronchitis. In this review, we describe COPD phenotypes that provide prognostication and/or indicate specific treatment. We also describe COPD-like phenotypes that do not necessarily meet the current diagnostic criteria for COPD but provide additional prognostication and may be the targets for future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.